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Non-genomic effects of the 
Pregnane X Receptor negatively 
regulate platelet functions, 
thrombosis and haemostasis
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Alexander R. Stainer1, Sarah K. AlOuda1, Marilena Crescente  1,6, Tanya Sage1, 
Amanda J. Unsworth1,7 & Jonathan M. Gibbins1*
The pregnane X receptor (PXR) is a nuclear receptor (NR), involved in the detoxification of xenobiotic 
compounds. Recently, its presence was reported in the human vasculature and its ligands were 
proposed to exhibit anti-atherosclerotic effects. Since platelets contribute towards the development 
of atherosclerosis and possess numerous NRs, we investigated the expression of PXR in platelets along 
with the ability of its ligands to modulate platelet activation. The expression of PXR in human platelets 
was confirmed using immunoprecipitation analysis. Treatment with PXR ligands was found to inhibit 
platelet functions stimulated by a range of agonists, with platelet aggregation, granule secretion, 
adhesion and spreading on fibrinogen all attenuated along with a reduction in thrombus formation 
(both in vitro and in vivo). The effects of PXR ligands were observed in a species-specific manner, and the 
human-specific ligand, SR12813, was observed to attenuate thrombus formation in vivo in humanised 
PXR transgenic mice. PXR ligand-mediated inhibition of platelet function was found to be associated 
with the inhibition of Src-family kinases (SFKs). This study identifies acute, non-genomic regulatory 
effects of PXR ligands on platelet function and thrombus formation. In combination with the emerging 
anti-atherosclerotic properties of PXR ligands, these anti-thrombotic effects may provide additional 
cardio-protective benefits.
Nuclear receptors (NRs) are well characterised for their genomic functions (transcriptional regulation), however, 
less is known about their non-genomic roles. Several NRs (such as LXR, PPARα/β/γ, RXR, RAR and FXR) have 
been identified in platelets, which upon ligation regulate platelet activity, thrombosis and haemostasis through a 
variety of mechanisms in a non-genomic manner1–7. The pregnane X receptor (PXR) forms a heterodimer with 
retinoid X receptor (RXR)8 and functions as a sensor, activated by xenobiotic and toxic endogenous compounds, 
leading to their metabolism and elimination through the upregulation of cytochrome P450 enzymes. PXR is pre-
dominantly expressed in liver and intestines9 and unlike other NRs, displays a large and flexible ligand-binding 
domain (LBD) that enables its binding with a diverse array of ligands that includes bile acids, pharmaceutical 
substrates, herbal medicines, environmental pollutants, and endobiotics10. Additionally, the LBD of PXR shows 
variation in amino acid sequence amongst different species11. Therefore, inter-species differences in the ligands 
that activate PXR have been reported. Consequently, human PXR is activated by ligands such as SR12813 and 
rifampicin, whilst they do not affect mouse PXR. Similarly, the PXR ligand, pregnenolone 16α-carbonitrile 
(PCN), is highly specific to rodents only12,13.
Increasing evidence identifies PXR to act as a potential therapeutic target for the treatment of a variety of 
patho-physiologies14. PXR ligands have demonstrated anti-atherosclerotic effects via increased cholesterol 
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clearance and HDL production in a mouse model of atherosclerosis15–17. Recently, PXR was reported to be 
expressed in the human vasculature (blood vessels, aortic endothelial and smooth muscle cells), where it func-
tions to detoxify circulating toxins and avert vascular damage by upregulating CYP 3A, 2B and 2C activity18.
Here, we report the presence of PXR in human platelets. Treatment of platelets with PXR ligands (SR12813 or 
rifampicin) attenuated platelet functions and thrombus formation (in vitro and in vivo) through a mechanism that 
is associated with the down-regulation of Src-family kinase (SFK) signalling.
Materials and Methods
Reagents. Bovine thrombin, rifampicin and 5-Pregnen-3β-ol-20-one-16α-carbonitrile (PCN) were pur-
chased from Sigma-Aldrich. Collagen was obtained from Nycomed. CRP-XL was from Professor R. Farndale 
(University of Cambridge). SR12813 was from Abcam (Cambridge, UK). Primary polyclonal anti-PXR (sc25381), 
monoclonal anti-RXRα/β/γ (sc46659), 14-3-3 ζ (sc-293415) and actin (sc-1615) antibodies were from SantaCruz. 
Monoclonal anti-PXR (ab41930), primary phospho anti-Lyn (Y396) (ab226778), Syk (Y525/526) (ab58575) and 
LAT (Y200) (ab68139) antibodies were from Abcam. Primary phospho anti-Src (Y418) (#44-660 G) was from 
ThermoFisher Scientific. Primary phospho anti-PLCγ2 (Y1217) (#3871), VASP (S157 and S239) (#3111 and 
#3114) and PKC (#2261) were purchased from Cell Signalling Technologies. Anti-phospho-Tyr 4G10 (#05-321) 
antibody was from Millipore. Fluorophore conjugated secondary antibodies, Fura-2AM and Alexa-488 conju-
gated phalloidin were from Life Technologies. PE-Cy5 anti-CD62P antibody was from BD Biosciences. FITC-
labelled anti-fibrinogen was from Dako. All other reagents were from previously described sources5,6. Humanised 
PXR transgenic mice [C57BL/6-Nr1i2tm1(NR1I2)Arte] were purchased from Taconic Biosciences (Denmank) and 
bred under licence at the bioresource unit of the University of Reading.
Human blood collection. Blood was collected with approval by the University of Reading Research Ethics 
Committee, and in accordance with the Declaration of Helsinki. Human blood was collected in 3.8% (v/v) citrate 
by venepuncture from aspirin free, healthy volunteers after obtaining their informed consent. Detailed method is 
available in the supplementary information. All methods performed in the study were carried out in accordance 
with the University of Reading guidelines and regulations concerning ethical approval, health and safety, the use 
of animals in experimentation and research quality assurance. Experimental protocols were approved by the 
University of Reading Research Ethics Committee and the Animal Welfare Ethical Review Board. Experiments 
using animals were approved and performed in accordance with a licence issued by the UK Home Office
Platelet preparation, aggregation and dense granule secretion assays. Platelet aggregation and 
dense granule secretion in washed platelets was determined using lumiaggregometry by measuring changes in 
optical density and ATP release, respectively. Detailed method is available in the supplementary information.
Immunofluorescence microscopy. Human (in PRP) stimulated with or without thromboxane A2 receptor 
agonist, U46619 (5 µM), were left to settle on poly-L-lysine coverslips for 1 hour at 37 °C before permeabilisation 
and blocking (0.2% Triton-X-100, 1% BSA, 2% donkey serum). Coverslips were then incubated with primary 
antibodies (PXR or RXR and GPIb) overnight (4 °C) and washed in PBS before staining with Alexa-fluor con-
jugated secondary antibodies for 1 hour at room temperature. Platelets were imaged on a Nikon A1-R confo-
cal microscope (100X magnification oil immersion lens). Detailed method is available in the supplementary 
information.
Immunoblotting and immunoprecipitation. Washed platelets (4 × 108 or 8 × 108 cells/ml) were lysed 
in an equal volume of NP40 buffer (300 mM NaCl, 20 mM Tris base, 2 mM EGTA, 2 mM EDTA, 1 mM PMSF, 
10 µg/ml aprotinin, 10 µg/ml leupeptin, 0.7 µg/ml pepstatin A, 2 mM sodium orthovanadate, 2% NP-40, pH 7.3), 
and proteins of interest were isolated using 1 μg/mL of appropriate antibodies. Detailed method is available in the 
supplementary information. Immunoblotting was performed using standard techniques as described in the sup-
plementary information. Levels of phosphorylated proteins were detected using fluorophore-conjugated second-
ary antibodies and visualised using a Typhoon FLA 9500 fluorimeter (GE healthcare) and quantified using Image 
Quant software version 8.1 (GE healthcare). Protein loading was assessed through reprobing for actin or 14-3-3ζ.
Fibrinogen binding and alpha granule secretion. Activation of the integrin αIIbβ3 and alpha-granule 
secretion were measured by determining levels of fibrinogen binding and P-selectin exposure on the platelet 
surface by flow cytometry using FITC-conjugated anti-fibrinogen and PE/Cy5-labelled anti-CD62P antibody, 
respectively. Using a BD Accuri C6 flow cytometer, 10,000 events were analysed using the CFlow Sampler soft-
ware. Detailed methods for both are available in the supplementary information.
Calcium mobilization. PRP was loaded with Fura-2 AM (2 µM) for 1 h at 30 °C and then washed platelets 
were prepared. Fura-2AM-loaded platelets were incubated with PXR ligands or vehicle prior to their activa-
tion. The ratio of emission values (excitation at 340/380 nm) was recorded using a NOVOstar plate reader (BMG 
Labtech) and converted to calcium concentration. Detailed method is available in the supplementary information.
Platelet spreading and clot retraction. Washed human platelets (2 × 107 cells/ml) treated with or with-
out PXR ligands were exposed to fibrinogen or collagen (100 µg/ml) coated coverslips for 45 minutes. Adhered 
platelets were fixed using 2% (v/v) paraformaldehyde and permeabilised with 0.2% (v/v) Triton-X-100. Thereafter, 
platelets were stained using Alexa488-conjugated phalloidin. Adherent platelets were imaged on a Nikon A1-R 
confocal microscope (100X magnification oil immersion lens). The number of platelets in different stages of 
spreading were obtained by counting, for each sample, the number of platelets in 5 randomly chosen fields of 
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view. Clot retraction was studied in thrombin (1 U/mL) stimulated PRP treated with or without PXR ligands for a 
period of 1 hour (37 °C). Clot weight was measured as a marker of clot retraction. Detailed methods are available 
in the supplementary information.
Thrombus formation in vitro. Human or mouse blood fluorescently labelled with lipophilic dye DIOC6 
was pre-incubated with vehicle or PXR ligands and perfused over a collagen-coated (100 µg/ml) microfluidic 
biochip (Cellix) at an arterial shear rate (20 dyn/cm2). Images of thrombi were obtained using a using Nikon A1-R 
Confocal microscope (20X objective) and fluorescence intensity was calculated. Detailed method is available in 
the supplementary information.
Thrombus formation in vivo and tail bleeding assay. Thrombosis in humanised PXR transgenic 
mice (hPXR) treated with SR12813 or vehicle that were administered intravenously was assayed following 
laser-induced injury by intravital microscopy. After laser-induced injury of the inner wall of cremaster muscle 
arterioles, accumulation of platelets was assessed. Fluorescence and bright-field images were recorded using an 
Olympus BX61W microscope with a 60 × /1.0 NA water immersion objective and a high-speed camera. Data 
was analysed using Slidebook5 software (Intelligent Imaging Innovations). Tail bleeding experiments following 
removal of the tail-tip were performed on 20–25 g hPXR mice, anesthetized with ketamine (100 mg/kg) and 
xylazine (10 mg/kg) injected intraperitoneally. Detailed methods are available in the supplementary information.
Statistical analysis. Data were analysed using ANOVA with Bonferroni post-test as indicated, or where 
appropriate by t-test. The Mann-Whitney U test was used to analyse tail bleeding and thrombosis assay. Data 
represent mean ± SD and P < 0.05 was considered to be statistically significant. Statistical analysis was performed 
using GraphPad Prism 7.0 software (California, USA).
Results
PXR is present in human platelets. Initial analysis of platelet lysates for the presence of PXR revealed a 
weak band representing the receptor. Therefore, immunoprecipitation was performed to enrich the sample with 
PXR to enhance its detection. The protein was immunoprecipitated from platelet lysates using a mouse anti-PXR 
antibody (targeting amino acids 1–40) and its presence was confirmed by immunoblotting with a rabbit anti-PXR 
antibody (targeting amino acids 101–260) (Fig. 1A). The sub-cellular localisation of PXR was studied in resting 
human platelets using immunofluorescence microscopy. The PXR (red stain) was noted to be distributed inside 
the platelet cytosol (green stain marks platelet surface GPIb) in a punctate arrangement (Fig. 1B). Previously, it 
has been reported that NRs such as RXR and PPARγ are secreted from platelets upon their activation19. This was 
evaluated for PXR in resting and activated (0.1 U/ml thrombin) permeabilised platelets using flow cytometry. The 
level of fluorescence associated with PXR in thrombin-activated platelets was reduced, in comparison with resting 
platelets, suggesting a reduction in the number of PXR molecules present inside the activated platelets, consistent 
with release or secretion (Fig. 1C,D).
PXR and RXR exists as heterodimers in human platelets. The formation of heterodimers between 
RXR and other NRs (PPARs, FXR, PXR, LXR) in nucleated cells is known20 and our previous work suggested the 
existence of RXR-LXR, RXR-PPARα and RXR-PPARγ heterodimers in human platelets6. The potential ability for 
PXR to interact with RXR in platelets was therefore examined. RXR and PXR were found to co-immunoprecipitate 
in both resting and activated platelets (Fig. 2A). Using immunofluorescence microscopy, a high degree of colocal-
isation between RXR (red) and PXR (blue) was observed in both resting and U46619-activated (5 µM) platelets 
(stained in green for GPIb (Fig. 2B)). A scatter plot demonstrated a clear relationship of fluorescence intensity 
points for RXR and PXR, clustering proportionally along a straight line (approximately 45 degrees to either axis), 
indicating a high level of colocalisation in resting and activated platelets (Fig. 2C). In alignment with this, the 
Pearson’s correlation coefficient (PCC), was found to be 0.94 and 0.92 between RXR and PXR in resting and acti-
vated platelets, respectively, indicating a strong co-localisation. There was no change in the extent of PXR-RXR 
colocalization between resting and activated platelets (Fig. 2D).
PXR ligands inhibit platelet aggregation to a range of platelet activators. The effects of two 
structurally distinct PXR ligands, SR12813 and rifampicin10 were evaluated on platelet aggregation, stimulated 
by various platelet activators. To maintain consistency in results, the concentration of each platelet agonist for 
each donor was optimized to attain 50% maximal aggregation (EC50) in 5 minutes. Treatment of platelets with 
SR12813 for 10 minutes reduced platelet aggregation mediated by collagen (EC50: 0.5–0.8 μg/ml) by 27% and 40% 
at 50 and 100 μM SR12813 (Fig. 3A), respectively, compared to vehicle (DMSO 0.1% v/v). Similar levels of inhi-
bition were observed with rifampicin treatment (Suppl. Fig. 1A). Increasing the incubation period of SR12813 
(Fig. 3B) or rifampicin (Suppl. Fig. 1B) to 20 minutes strongly enhanced inhibition against collagen-stimulation, 
which may reflect the rate of transit of PXR ligands across the plasma membrane. Aggregation mediated by the 
G protein–coupled receptor (GPCR) agonist thrombin (EC50: 0.03–0.04 U/ml) was also attenuated by SR12813 
or rifampicin (10-mins incubation). 50 and 100 μM of SR12813 demonstrated 35% and 42% reduction in aggre-
gation respectively at 3-minute post-activation by thrombin in comparison with 5-minutes interval, which was 
around 15% and 23%, respectively (Fig. 3C). Similar observations were made with rifampicin (Suppl. Fig. 1C). In 
addition to this, both the PXR ligands inhibited U46619-mediated platelet aggregation (EC50 range: 0.2–0.4 μM) 
(Suppl. Fig. 1D,E) and ADP (EC50 range: 5–10 μM) (Suppl. Fig. 1F,G), indicating that the effects of PXR ligands 
are widespread (acting on both GPVI and GPCR-mediated platelet activation) and not restricted to a specific 
platelet activation pathway.
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PXR ligands inhibit integrin αIIbβ3 activation and platelet secretion. The affinity upregulation 
of integrin αIIbβ3 following platelet activation is essential for platelet aggregation. Therefore, the effects of PXR 
ligands on the extent of CRP-XL (EC50: 0.25 µg/ml) or thrombin (EC50: 0.05 U/ml) induced fibrinogen bind-
ing to integrin αIIbβ3 were evaluated in PRP using flow cytometry. In alignment with reduced aggregation, 
CRP-XL-induced fibrinogen binding was inhibited by 52% at 100 μM SR12813, in comparison to vehicle-control 
(DMSO 0.1% v/v) (Fig. 3D). Thrombin-stimulated fibrinogen binding was also attenuated by 100 µM SR12813 
by 40% (Fig. 3E). Similar effects were demonstrated by rifampicin on CRP-XL or thrombin stimulation (Suppl. 
Fig. 2A). To investigate the effects of PXR ligands on degranulation, the extent of alpha and dense granules 
secretion was evaluated by measuring P-selectin exposure on the platelet surface and ATP release, respectively. 
SR12813 (Fig. 3F,G) and rifampicin (100 μM) (Suppl. Fig. 2B) caused 40% and 30% reduction in CRP-XL (0.25 µg/
ml) or thrombin-stimulated (0.05 U/ml) P-selectin exposure, respectively, compared to vehicle (DMSO 0.1% 
v/v). ATP release following stimulation by either collagen (1 µg/ml) or thrombin (0.05 U/ml) was also attenuated 
following pre-treatment of platelets with SR12813 (Fig. 3H,I) or rifampicin (Suppl. Fig. 2C,D).
In addition to degranulation, activated platelets synthesise TxA2 from arachidonic acid through the actions of 
COX-1 and TxA2 synthase. TxA2 synthesis and release activate more platelets at the site of injury, thus, amplifying 
the aggregation response. SR12813 treatment significantly down-regulated both CRP-XL (1 μg/ml) or thrombin (0.05 
U/ml) evoked TxB2 (a stable metabolite of TxA2) production by washed platelets (Fig. 3J,K). Higher concentrations 
of platelet agonists were used to ensure maximum secretion and synthesis of ATP and TxB2 from activated platelets 
for effective detection. Consequently, incubation time with PXR ligands was prolonged (20 mins) in these assays.
Collagen-evoked platelet aggregation depends partially on the release of secondary mediators. Since PXR 
ligands can inhibit aggregation instigated by both ADP and U46619, we investigated whether the inhibitory 
effects of PXR ligands against collagen-stimulation (10 µg/ml) are independent of their ability to reduce second-
ary mediator effects. Given the high concentration of collagen used in this assay, SR12813 (100 µM) on its own did 
Figure 1. PXR is present in human platelets. (A) PXR was immunoprecipitated (IP: PXR) from human platelets 
(IP: PXR) using a mouse monoclonal antibody and blotted with a rabbit polyclonal antibody. Human whole 
platelet lysates (WPL) and antibody used to IP (Ab: PXR) PXR were used as positive and negative controls, 
respectively. Cropped western blot image is representative of 3 separate experiments using different donors. 
Full length blot is shown in Supplementary Fig. 8a (B) The localisation of PXR in human resting platelets was 
investigated using immunofluorescence microscopy. PXR (in red) and membrane GPIb receptors (in green) 
were stained using anti-PXR and anti-GPIb antibodies. Platelets without primary antibody treatment were 
used as negative controls. (C) Flow cytometry was used to examine the median fluorescence level of PXR in 
permeabilised resting and activated (with 0.1 U/ml thrombin) human platelets, incubated with a PXR antibody 
or the equivalent rabbit IgG isotype control. (D) Median fluorescence intensity (MFI) associated with the PXR 
positive platelets in resting and activated platelets. Data represent mean ± SD (N ≥ 3), *P < 0.05 was calculated 
by Student T-test. Figure adapted from corresponding PhD thesis48.
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not affect platelet aggregation (Suppl. Fig. 2E), however, the inhibitory effects of SR12813 (100 µM) were found to 
be additive to the inhibition caused by saturating concentrations of secondary mediator inhibitors; indomethacin 
(20 µM; TxA2 synthesis blocker) and ADP receptor antagonists (1 µM cangrelor and 100 µM MRS2179). This indi-
cates that the effects of SR12813 on collagen-mediated platelet aggregation are not solely dependent on its effects 
on secondary mediator release during activation (Suppl. Fig. 2E).
Species-specific effects and inhibition of thrombus formation in vitro by human and mouse 
PXR ligands. As mentioned earlier, a dissimilarity exists in the sequence of the PXR LBD between species, 
with only 76% amino acid sequence similarity in the LBD between human and mouse PXR10. This results in a 
high degree of inter-species differences in ligands that activate PXR. This property was explored to assess whether 
the effects of PXR ligands are likely to be mediated through binding to PXR protein in platelets. Consequently, the 
effects of human (SR12813) or mouse (PCN) PXR ligands on CRP-XL-stimulated fibrinogen binding in human 
and mouse platelets were investigated. It was not possible to directly compare the responses of human and mouse 
platelets as their activation profile is quite different towards the similar concentrations of platelet agonists. For 
instance, a concentration of 0.25 μg/ml of CRP-XL was sufficient to activate human platelet samples to study 
the effects of human PXR ligands, however, this produced a modest effect on mouse platelets. Consequently, 
the CRP-XL concentration was enhanced to 0.5 μg/ml for experiments using mouse PRP. In comparison to 
vehicle-control (DMSO 0.1% v/v), 100 μM of SR12813 reduced CRP-XL-stimulated (0.25 μg/ml) fibrinogen 
binding in human platelets by 50% (Fig. 3D). However, SR12813 did not cause any change in mouse platelet 
responses stimulated with CRP-XL (0.5 μg/ml) (Fig. 4A). Similarly, mouse PXR ligand, PCN (100 μM), inhib-
ited CRP-XL-evoked fibrinogen binding in mouse platelets by 25% in comparison to vehicle-control (DMSO 
0.5% v/v), whereas, no effect was observed in human platelets (Fig. 4B). These findings not only demonstrate 
species-specific effects of PXR ligand but also provides evidence that the effects of PXR ligands are mediated via 
PXR in human and mouse platelets.
Figure 2. PXR and RXR interact and co-localise in human platelets. (A) RXR was immunoprecipitated 
from human washed platelets (8 × 108 cells/ml) using a mouse monoclonal anti-RXR antibody. Immunoblot 
analysis was followed with the addition of a rabbit polyclonal anti-PXR antibody and its detection using a 
secondary antibody that does not recognize denatured IgG. The presence of RXR was also confirmed in the 
same samples. Cropped representative blot of 3 separate experiments is shown. Full length blot of PXR and 
RXR is shown in Supplementary Fig. 8Bi,ii respectively (B) Localisation of PXR and RXR in resting and 
activated (with 5 µM U46619 in the presence of integrelin) permeabilised human platelets was investigated 
using immunofluorescence microscopy. RXR (in red), PXR (in blue) and membrane GPIb receptors (in green) 
were stained using anti-RXR, anti-PXR and anti-GPIb antibodies respectively. Representative figures show 
the distribution of RXR and PXR in resting and activated platelets. (C) Scatter plots between the fluorescence 
intensity points of RXR and PXR in resting and activated platelets represent the degree of colocalisation 
between RXR and PXR. (D) The Pearson correlation coefficient (PCC) representing the degree of colocalisation 
between RXR-PXR in resting and activated platelets. PCC was quantified for 12 platelets using different fields. 
Data represent mean ± SD, **P < 0.01 and ***P < 0.001 was calculated by Student T-test. Figure adapted from 
corresponding PhD thesis48.
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Given the ability of PXR ligands to regulate numerous aspects of platelet activation, we investigated their 
effects on thrombus formation in vitro. Treatment with SR12813 (100 µM) for 20-minutes inhibited thrombus 
development in contrast to vehicle (DMSO 0.1% v/v) (Fig. 4C). Rifampicin (100 µM) treatment also reduced 
thrombus formation (Suppl. Fig. 3A). Furthermore, the initial kinetics of thrombus-development in PXR 
ligand-treated samples were inhibited in comparison to vehicle-control, which might be due to reduced adhesion 
of platelets to collagen.
The thrombus formation assay was also performed to study the species-specific effects of PXR ligands. In com-
parison to vehicle (DMSO 0.5% v/v), 20-minutes treatment with mouse PXR ligand, PCN (100 μM), caused a 50% 
reduction in thrombus formation in mouse blood (Fig. 4E). In contrast, thrombus formation in PCN (100 μM) 
treated human blood was not altered (Fig. 4F). To further confirm the species-specific nature of PXR ligands, the 
effect of human PXR ligand (SR12813) was evaluated in mouse blood. As discussed previously, SR12813 reduced 
thrombus formation in human blood (Fig. 4C), but thrombus development in mouse blood treated with SR12813 
was similar to vehicle-treated samples (Fig. 4D).
Figure 3. SR12813 inhibits platelet aggregation, integrin αIIbβ3 activation and secretion. Human washed 
platelets (4 × 108 cells/ml) pre-treated with SR12813 or vehicle-control (DMSO, 0.1% v/v) were stimulated 
with (A,B) collagen (EC50: 0.5–0.8 µg/ml) or (C) thrombin (EC50: 0.03–0.04 U/ml). Representative aggregation 
traces are shown. Quantified data displays the percentage of aggregation (vehicle-treated samples represent 
100% aggregation) at the end of 5 minutes. (D) Human PRP treated with SR12813 or vehicle for 10 minutes was 
stimulated with CRP-XL (EC50: 0.25 µg/ml) or thrombin (EC50: 0.05 U/ml) and fibrinogen binding to integrin 
αIIbβ3 was measured using flow cytometry. (E) P-selectin exposure was measured in SR12813 treated PRP, 
stimulated with CRP-XL (0.25 µg/ml) or thrombin (0.05 U/ml). Vehicle-treated control is defined as 100% 
fibrinogen binding and P-selectin exposure. ATP release was monitored for 5 minutes in washed platelets 
(4 × 108 cells/ml), incubated with SR12813 or vehicle-control for 20 mins and stimulated with (F) collagen (1 µg/
ml) or (G) thrombin (0.05 U/ml). Representative traces and quantified data are shown. Vehicle-treated samples 
represent 100% ATP secretion. (H) TxB2 production was evaluated in human washed platelets (4 × 108 cells/
ml) pre-incubated with SR12813 or vehicle control for 20 min and stimulated by CRP-XL (1 μg/ml) or thrombin 
(0.05 U/ml) for 5 minutes. Data represent mean ± SD (n ≥ 3), *P < 0.05, **P < 0.01 and ***P < 0.001 was 
calculated by one-way ANOVA. Figure adapted from corresponding PhD thesis48.
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PXR ligands inhibit thrombosis and haemostasis in mice. Given the negative-regulation of throm-
bus formation in vitro, the acute effect of human PXR ligand (SR12813) was evaluated in vivo. As explained 
earlier, PXR ligands exhibit species-specific responses in platelets; therefore, the effects of SR12813 were studied 
on humanised PXR transgenic mice (hPXR). These mice lack the endogenous PXR gene, which is replaced with 
human PXR gene and is reported to be responsive towards human PXR ligands and not to mouse PXR ligand21–24. 
Prior to the investigation, the expression levels of integrin α2β1, αIIbβ3, GPIb and GPVI (Suppl. Figs. 3B–E) 
receptors on hPXR were compared with background C57BL/6 mice and were found to be similar.
The acute effects of PXR ligands on in vivo thrombus formation were evaluated by studying laser-induced 
thrombosis in mouse cremaster muscle arterioles. As shown in Fig. 5A, the initial kinetics of thrombus formation 
in SR12813 (100 µM) treated mice was similar to vehicle (DMSO 0.1% v/v) (Fig. 5B), however, the overall size of 
thrombi was substantially reduced by 80% (Fig. 5C). Moreover, maximum fluorescence intensity of thrombus was 
reduced by 45% in SR12813 treated mice, consistent with the formation of smaller thrombi (Fig. 5D). Together these 
results suggest PXR ligands elicit anti-thrombotic effects. We cannot exclude the effects of other cell types on throm-
bosis, although the level of inhibition in the presence of SR12813 was comparable to its ability to attenuate thrombus 
formation in vitro, assays where vasculature or endothelial cells are not present. This suggests that PXR-mediated 
down-regulation of thrombus formation might be independent of the effects from other vascular cell types.
Given the observed anti-thrombotic properties of PXR ligands, the effect of SR12813 on haemostasis was meas-
ured by a tail-bleeding assay performed on hPXR mice. The mean time to cessation of bleeding was prolonged to 
approximately 500 seconds in mice treated with SR12813, in comparison vehicle-treated mice (275 seconds), demon-
strating that acute PXR ligand treatment increases bleeding and impairs haemostasis (Fig. 5E). The tail-bleeding 
assay takes into account both platelet-function and and the coagulation processes25–27 and therefore, besides the 
effects of PXR ligands on platelet activation, the effects of PXR ligands on coagulation cannot be excluded.
PXR ligands inhibit outside-in signaling. Binding of fibrinogen to integrin αIIbβ3 initiates outside-in 
signalling in platelets, which facilitates platelet spreading and clot retraction, required for the stability of the 
thrombus. Given the ability of PXR ligands to inhibit events associated with inside-out signalling such as 
Figure 4. PXR ligands function in a species-specific manner and inhibit thrombus formation in vitro. Human 
or mouse PRP was treated with (A) SR12813 or (B) PCN or vehicle-control (0.1% DMSO v/v for SR12813 or 
0.5% v/v DMSO for PCN) prior to stimulation with CRP-XL (0.25 µg/ml for human platelets and 0.5 µg/ml for 
mouse platelets). The level of fibrinogen binding to integrin αIIbβ3 was measured using flow cytometry. Human 
or mouse blood, incubated with DiOC6 (5 μM) were perfused through collagen-coated (100 μg/ml) microfluidic 
chips at arterial flow rate (20 dyne/cm2) after treatment with (C,D) SR12813 or (E,F) PCN or vehicle-
control (0.1% DMSO v/v for SR12813 or 0.5% v/v DMSO for PCN) for 20 minutes. Representative images 
display thrombus formation. Quantified data represent mean thrombus fluorescence intensity normalised to 
fluorescence level of the vehicle-treated sample obtained at the end of the assay. Data represent mean ± SD 
(n ≥ 3) where *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 was determined by student t-test or one-
way ANOVA for fibrinogen binding assay and two-way ANOVA for in vitro thrombus formation assay. Figure 
adapted from corresponding PhD thesis48.
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aggregation, integrin αIIbβ3 upregulation and degranulation, their effects on outside-in signalling were also 
evaluated. In comparison to vehicle, fewer platelets were observed adhered to fibrinogen (in 45 minutes) fol-
lowing 20-minutes treatment with SR12813 (50 or 100 μM) (Fig. 6A). Additionally, SR12813 was also found to 
hinder platelet spreading with fewer platelets forming lamellipodia and increased numbers of cells remaining at 
the adhered or filopodial phases (Fig. 6A). Similar observations were noted with rifampicin treatment (Suppl. 
Fig. 4A). Consistent with this, an increase in clot weight (indicative of reduced clot retraction, a process driven 
by integrin αIIbβ3 outside-in signalling) was observed in samples treated with SR12813 (Fig. 6B) or rifampicin 
(Suppl. Fig. 4B) after 90 minutes, compared to vehicle-treated samples. These data along with previous findings 
suggest the ability of PXR ligands to modulate bi-directional signalling transmitted via integrin αIIbβ3.
To test whether the reduced adhesion and spreading were restricted to the functions of integrin αIIbβ3, simi-
lar experiments were performed on collagen (which is dependent on integrin α2β1 and GPVI). Platelet adhesion 
and spreading on collagen was also found to be inhibited with SR12813 (Fig. 6C) and rifampicin (Suppl. Fig. 4C) 
treatment. These findings along with observations of reduced thrombus formation (in vitro) suggest that PXR 
ligand-mediated reduction in thrombus formation might be partly due to the diminished platelet adhesion to 
collagen.
PXR ligands inhibit GPVI-mediated signalling pathway. Having identified anti-thrombotic effects of 
PXR ligands, we determined the mechanism by which PXR ligands elicit anti-platelet activity. We and others have 
previously described the involvement of NRs in the regulation of platelet inhibitory signalling pathways, notably 
activation of the cGMP/PKG and cAMP/PKA linked pathways1,4,6. To determine whether PXR, which we have 
shown heterodimerises with RXR (which regulates PKA activity)6 acts in a similar manner, VASP S157 and VASP 
S239, markers of PKA and PKG activity respectively, were determined in PXR ligand treated platelets. Neither of 
the PXR ligands was found to activate PKA (Suppl. Fig. 5A,B) or PKG (Suppl. Fig. 5C,D) activity, indicating that 
PXR negatively regulates platelet function independently of these inhibitory signalling pathways.
Since PXR ligands were observed to attenuate collagen/CRP-XL-mediated platelet activation, their effects on 
the GPVI-signalling pathway were investigated. Platelets were stimulated for 90 seconds under non-aggregating 
conditions [EGTA (1 mM), indomethacin (20 µM), cangrelor (1 µM) and MRS2179 (100 µM)] to block signalling 
via secondary mediators and ensure the study of primary GPVI-signalling. Consequently, CRP-XL concentra-
tion was increased (1 µg/ml) to visualise the phosphorylation of GPVI-signalling components by immunoblot 
analysis6. Consistent with our earlier observations, pre-treatment of platelets (20-minutes) with 50 and 100 µM of 
SR12813 (Fig. 7A) or rifampicin (Suppl. Fig. 6A) significantly reduced CRP-XL-evoked total tyrosine phospho-
rylation in comparison to vehicle (DMSO 0.1% v/v). Significant attenuation of early GPVI-signalling events, spe-
cifically phosphorylation of Syk (at its auto-phosphorylation site Y525/526) by SR12813 (Fig. 7B) or rifampicin 
Figure 5. SR12813 inhibit thrombosis and haemostasis. Laser-induced injury model was used to measure 
thrombosis in hPXR mice through intravital microscopy. Vehicle-control (DMSO 0.1% v/v) or SR12813 
(100 μM) was administered intravenously to mice and incubated for 20 minutes. Platelets were labelled with 
Alexa488–conjugated anti-GPIb antibody. (A) Representative images of thrombi obtained at different time 
intervals. (B) Data represent median fluorescence intensity, measured for 8 to 10 thrombi from 3 mice each 
of control and SR12813 treated groups. (C) Thrombus-size was calculated using area under the median 
fluorescence intensity curve of each thrombi. (D) Mean of maximum fluorescence intensity of the thrombus. 
(E) Tail bleeding was performed on hPXR mice pre-treated with vehicle or SR12813 (100 μM) for 20 min 
(n = 7). Data represent mean ± SD (n ≥ 3) where *P < 0.05, **P < 0.01 and ***P < 0.001 was determined by 
nonparametric Mann–Whitney U test. Figure adapted from corresponding PhD thesis48.
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(Suppl. Fig. 6B) was also observed. Following this, CRP-XL-stimulated phosphorylation of Linker for Activation 
of T cells (LAT) at site Y200 was also down-regulated by SR128123 (Fig. 7C) or rifampicin (Suppl. Fig. 6C) treat-
ment along with the inhibition of PLCγ2 phosphorylation level (Fig. 7D) (Suppl. Fig. 6D) at Y1217.
As expected, PLCγ2-dependent downstream processes such as calcium-mobilisation were inhibited by both 
SR1813 (Fig. 7E) and rifampicin (Suppl. Fig. 6E) treatment, along with the reduction of protein kinase C (PKC) 
phosphorylation (Fig. 7F) (Suppl. Fig. 6F), both of which are essential for the regulation of cytoskeletal rearrange-
ment, degranulation and integrin αIIbβ3 upregulation28. Together, these observations highlight a potential role 
for PXR ligands in regulating GPVI-receptor signalling.
Inhibition of Src family kinases (SFKs) as a general mechanism for PXR function. Platelet 
function stimulated by GPVI, integrin αIIbβ3 and GPCRs are all dependent on signalling via SFKs29. The 
down-regulation of both early and late GPVI signalling events suggested the involvement of specific target ele-
ments of PXR ligands in GPVI signalling, facilitating this cascade of inhibition. Given the down-regulation of 
Syk phosphorylation, these elements are likely to act at a level that is upstream of Syk, such as SFKs. Therefore, 
the regulation of SFK activity by PXR ligands was monitored. Treatment with SR12813 (Fig. 8A) and rifampicin 
(Suppl. Fig. 7A) (50 and 100 µM) reduced CRP-XL-induced autophosphorylation of Src at Y41830 and Lyn at 
Y39631 (Fig. 8B) (Suppl. Fig. 7B), in comparison with vehicle (DMSO 0.1% v/v). To determine whether the regula-
tion of SFKs marks a general mechanism of action for PXR ligands, signalling pathways initiated by other platelet 
receptors dependent on SFKs (such as CLEC-2 and integrin αIIbβ3) were examined29.
Figure 6. SR12813 inhibit outside-in signalling in platelets. Human washed platelets (2 × 107 cells/ml) were 
treated with SR12813 (50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 minutes and added onto (A) 
fibrinogen (100 μg/ml) or (C) collagen-coated coverslips for 45 mins. Platelets were stained using Alexa-Fluor 
488 for visualisation using a Nikon A1-R confocal microscope (100X). 5 images were captured of each sample 
at random locations. Representative images of platelet adhesion and spreading are shown. Cumulative data 
of platelets adhered in each sample is shown. Spreading platelets were divided into 3 classes: (adhered but not 
spread; filopodia: spreading platelets and lamellipodia: fully spread). Results expressed (as relative frequency) 
as the percentage of the total number of platelets adhered. (B) Human PRP was incubated with SR12813 (20, 
50 and 100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 minutes. Extent of clot retraction was determined 
by comparing clot weight after 60 minutes. Representative image of clot retraction after the end of the assay is 
shown. Cumulative data represent clot weight (in mg) of samples treated with SR12813 compared with vehicle-
control. Data represent mean ± SD (n ≥ 3), *P < 0.05, **P < 0.01 and ***P < 0.001 was calculated by one-way 
ANOVA. Figure adapted from corresponding PhD thesis48.
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As was observed with other platelet agonists, SR12813 (Suppl. Fig. 7C) and rifampicin (Suppl. Fig. 7D) were 
found to attenuate platelet aggregation stimulated by CLEC-2 agonist rhodocytin (100 nM). Consistent with this, 
SR12813 (Fig. 8C) and rifampicin (Supplemental Fig. 7E) were also able to significantly diminish rhodocytin 
(100 nM) induced Src phosphorylation (Y418). The stimulation time with rhodocytin was enhanced (120 secs) to 
detect phosphorylation considering the long lag-phase associated with the initiation of rhodocytin-evoked plate-
let aggregation. To further support a general role for PXR ligand-dependent down-regulation of SFK activity, Src 
phosphorylation was also found to be attenuated in platelets treated with SR12813 (Fig. 8D), following adhesion 
to fibrinogen (100 µg/ml). Interestingly, no alteration in Src phosphorylation was observed in rifampicin-treated 
samples (Supplemental Fig. 7F). This might be attributed to the experimental challenges of examining signalling 
stimulated by fibrinogen under static conditions. Altogether these findings suggest that PXR ligands potentially 
mediate their inhibitory effects on platelet function via the down-regulation of SFKs activity.
Discussion
Platelets are vital therapeutic targets for the treatment of cardiovascular diseases including atherothrombosis32. 
Current treatment includes the usage of anti-platelet drugs/therapies that prevent platelet activation by inhibiting dif-
ferent platelet signalling pathways33. These treatment regimens are effective, however, numerous side-effects (such as 
bleeding and drug resistance) limit their successful use34. Therefore, the development of newer strategies with minimal 
side-effects is required. NRs expressed in platelets have been proposed to exhibit antithrombotic effects35. In this study, 
we report the expression of PXR in platelets and the ability of its ligands to regulate platelet function and thrombosis.
Figure 7. SR12813 negatively regulate GPVI-mediated signalling. Platelets (4 × 108 cells/ml) were pre-treated 
with vehicle (DMSO 0.1% v/v) or SR12813 (0, 50 and 100 μM) for 20 minutes and stimulated with CRP-XL 
(1 μg/ml) for 90 seconds in the presence of indomethacin (20 μM), cangrelor (1 μM), MRS2179 (100 μM) 
and EGTA (1 mM). Samples were tested for (A) Total tyrosine, (B) Syk (Y525/526), (C) LAT (Y200), (D) 
PLCγ2 (Y1217) and (F) PKC substrate phosphorylation. Representative immunoblots are shown. Levels of 
phosphorylation were quantified and expressed as a percentage of untreated (vehicle) controls. 14–3–3-ζ 
or actin was used as a loading control. Full length blots are shown in supplementary Fig. 9 (E) Calcium 
mobilisation was evaluated in Fura-2AM loaded platelets (4 × 108 cells/ml) incubated with SR12813 (50 and 
100 μM) or vehicle-control (DMSO 0.1% v/v) for 20 min prior to stimulation with CRP-XL (0.25 μg/ml). 
Traces of CRP-XL-stimulated calcium mobilisation over a period of 5 minutes are shown. Cumulative data 
(peak calcium levels) of calcium mobilisation. Data represent mean ± SD (n ≥ 3) where *P < 0.05, **P < 0.01, 
***P < 0.001 and ****P < 0.0001 was determined by One-way ANOVA. Figure adapted from corresponding 
PhD thesis48.
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Acute effects of PXR ligands were investigated, noting that the principal ligands for this receptor required high 
concentrations (10–100 µM for this study) to elicit acute biological effects36. It is reported that the ligands that 
activate PXR require micromolar concentrations, generally two to three orders of magnitude higher than con-
centrations found circulating in plasma36 and lower than the concentrations used in this study. Sub-micromolar 
concentrations of PXR ligands are sufficient to elicit genomic effects through regulation of gene expression in 
nucleated cells. Notably, the work presented here reveals the non-genomic effects of these ligands in anucleated 
platelets. Given the likely differences in the mechanism of genomic and non-genomic functions of NRs, including 
PXR, it is not possible to directly compare features of these responses such as EC50. Indeed, our group has previ-
ously shown that NRs (such as PPARγ, LXR, RXR, and FXR) in platelets regulate non-genomic functions that are 
distinct from genomic regulation2,4–6,35. Genomic effects of NRs are usually determined via cell-based reporter 
assays that involve exposing transcription factors (such as PXR) to their ligands for prolonged durations (hours 
or days)10,37, whereas the time frame in which non-genomic effects are elicited ranges from a few seconds to a few 
minutes and appears to require acute exposure to higher concentrations of NR ligands38. Further work will be 
required to establish the molecular basis of PXR and other NRs in platelets.
Treatment of platelets with PXR ligands resulted in attenuation of multiple aspects of platelet activa-
tion including aggregation, integrin αIIbβ3 activation and granule secretion. A trend of inhibition (although 
non-significant) was observed at low concentrations (10 and 20 μM) of PXR ligands. This is relevant as clinical 
administration of rifampicin (600 mg) to treat tuberculosis can achieve such peak plasma levels39–41. Increasing 
the acute treatment time of platelets with PXR ligands was found to enhance the anti-platelet effects of PXR lig-
ands and as such further work is needed to determine the effects of chronic exposure to low concentrations of 
PXR ligands on platelet activity and thrombosis.
In platelets, apart from PXR, RXR also interacts with LXR6, PPARα6 and PPARγ6,19, although, the role of such 
heterodimers in non-genomic functions is unclear and requires further investigation. Platelets possess mRNA, capa-
ble of undergoing a minor level of translation42. Recently RARα was identified to regulate protein synthesis to some 
extent by its binding to a subset of mRNAs in human platelets43. Hence, it is possible that other NRs including PXR 
(in a bound or unbound state with RXR) may also contribute to some level of protein translation even in the absence 
of a nucleus44,45. To date, we have found no evidence to indicate the formation of NR homodimers in platelets.
PXR ligands down-regulated CRP-XL-mediated calcium-mobilisation and activation of PKC. This obser-
vation coupled with the previously reported abilities of PPARγ2, RXR6, LXR5 and FXR4 ligands to modulate 
calcium-mobilisation identifies a potentially common and fundamental role of NR ligands in regulating calcium 
homeostasis in platelets. In addition to PXR, other NRs such as LXR5 and PPARγ2 have also been identified to regulate 
the GPVI signalling pathway, whereas RXR6, PPARα1, PPARβ46 and FXR4 function by modulating cyclic nucleotide 
signalling in platelets. This suggests that platelet NRs have overlapping and distinct mechanisms of action in platelets35.
The inhibition of CRP-XL-induced downstream signalling events in platelets was identified to be an outcome 
of reduced phosphorylation of SFKs (Src and Lyn), key regulators of upstream signalling events. Besides GPVI, 
Figure 8. SR12813 inhibits tyrosine phosphorylation of SFKs proximal to GPVI, CLEC-2 and integrin αIIbβ3 
receptors. Platelets (4 × 108 cells/ml) were pre-treated with vehicle-control (DMSO 0.1% v/v) or SR12813 (0, 
50 and 100 μM) for 20 minutes and stimulated for (A, B) 90 seconds with CRP-XL (1 μg/ml) or (C) 120 seconds 
with rhodocytin (100 nM) in the presence of indomethacin (20 μM), cangrelor (1 μM), MRS2179 (100 μM) and 
EGTA (1 mM). (D) Washed platelets (4 × 108 cells/ml), pre-treated with SR12813 (0, 50 and 100 μM) or vehicle-
control were exposed to fibrinogen-coated wells (100 μg/ml) of a tissue culture plate and allowed to adhere for 
30 minutes. Samples were tested for Src (Y418) or Lyn (Y396) phosphorylation. Representative immunoblots 
are shown. The phosphorylation levels were quantified and expressed as a percentage of untreated (vehicle) 
controls. Actin was used as a loading control. Full length blots are shown in supplementary Fig. 9 and 10. 
Results are mean ± SD (n ≥ 3), *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 was calculated by one-
way ANOVA. Figure adapted from corresponding PhD thesis48.
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SFKs regulate signalling downstream of several other platelet receptors that include integrin αIIbβ3 and α2β1, 
CLEC-2, FcRγIIA and GPIb-IX-V receptor and therefore play a fundamental role in platelet activation29. SR12813 
treatment negatively-regulated Src phosphorylation, proximal to integrin αIIbβ3, which ensures thrombus sta-
bility via the regulation of outside-in signalling. The mechanism by which, PXR regulates the phosphorylation of 
SFKs requires further exploration. Given the ability of NRs such as LXR5 and PPARγ2 to bind with key signalling 
molecules of the GPVI pathway and modulate signalling, it is possible that PXR follows a similar mechanism 
and interacts with one or more GPVI signalling components to regulate signalling. However, the interaction of 
PXR with SFKs, Syk, LAT or PLCγ downstream of GPVI was not observed in this study. There remains a range 
of other potential points of interaction to explore such as the GPVI/FcRγ complex that might facilitate this effect. 
Consistent with the inhibition of GPVI signalling, thrombus formation, both in vitro and in vivo was found to be 
reduced considerably by PXR ligands, which might be a combined outcome of reduced activity of SFKs down-
stream of GPVI, α2β1, GPIb-V-IX and integrin αIIbβ3. Furthermore, Src phosphorylation was also attenuated 
by PXR ligands, downstream of CLEC-2, which provides additional evidence that PXR ligands broadly affect the 
activity of SFKs in multiple signalling pathways and thus elicit their effects.
PXR is naturally promiscuous with its activating ligands representing a diverse array of structurally different 
compounds. However, this promiscuity is also specific in nature as its activators can structurally differ from 
non-activators by only a few atoms, suggesting that PXR binds to a diverse but precise array of compounds, a 
feature referred to as “directed promiscuity”47. In this study, we also devised strategies to rule out non-specific 
effects of PXR ligands. Firstly, we used two different PXR ligands (SR12813 and rifampicin) that have the highest 
affinity towards this receptor and are also structurally distinct from each other. In addition to this, PXR ligands 
demonstrated species-specific responses to PXR ligands. Human or mouse PXR ligands did not affect mouse 
or human platelet activation (as demonstrated via integrin αIIbβ3 activation and in vitro thrombus formation 
assays) respectively, while human PXR ligands significantly inhibited human platelets and mouse PXR ligands 
reduced mouse platelet activation. This is plausible only when the effects of PXR ligands are mediated via PXR. 
While systemic knock-out models are ideal to test the specificity of ligands, in many circumstances, deletion 
of transcription factors can lead to far-reaching effects on cell biogenesis and their functions, due to potential 
effects on the expression of many proteins. It is for this reason that humanised PXR mice were used in this study. 
In this study, the use of PXR antagonists was avoided, since most NR antagonists are characterised as such due 
to their effects on the regulation of gene expression. Since the effects of NR agonists on platelets are mediated by 
alternative, non-genomic mechanisms, and noting our previous observation that some NR antagonists (e.g. RXR) 
exert similar effects on platelets to respective receptor agonists6, we anticipated that this approach may produce 
a confusing picture. This reinforced our decision to explore the mode of action of PXR ligands in platelets using 
a genetic approach in mice.
In summary, our study demonstrates the anti-thrombotic properties of PXR ligands. In addition to the 
already identified anti-atherosclerotic effects of PXR15–17, these findings suggest the potential use of PXR as a 
cardio-protective drug target. PXR ligands were also associated with impaired haemostasis and therefore their 
potential development into effective therapeutic agents would require careful balancing of anti-platelet effects 
and bleeding risk.
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